Compare · NVO vs UNCY
NVO vs UNCY
Side-by-side comparison of Novo Nordisk A/S (NVO) and Unicycive Therapeutics Inc. (UNCY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and UNCY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 1030.0x UNCY ($177.8M).
- Over the past year, NVO is down 45.7% and UNCY is down 26.2% - UNCY leads by 19.5 points.
- Both names hit the wire about 8 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 4 for UNCY).
- Company
- Novo Nordisk A/S
- Unicycive Therapeutics Inc.
- Price
- $41.01-4.51%
- $6.66-3.76%
- Market cap
- $183.15B
- $177.8M
- 1M return
- -10.44%
- -15.27%
- 1Y return
- -45.66%
- -26.16%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 8
- 8
- Recent ratings
- 25
- 4
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Unicycive Therapeutics Inc.
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest UNCY
- Unicycive Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form S-3 filed by Unicycive Therapeutics Inc.
- SEC Form 4 filed by Director Kenkare-Mitra Sara
- SEC Form 4 filed by CEO Gupta Shalabh K.
- SEC Form 4 filed by EVP, Corporate Strategy Jermasek Douglas
- SEC Form 4 filed by CFO Townsend John
- SEC Form 4 filed by EVP, Pharmaceuticals and BD Gupta Pramod
- SEC Form 4 filed by Director Laumas Sandeep
- Amendment: SEC Form SCHEDULE 13G/A filed by Unicycive Therapeutics Inc.
- Unicycive Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits